Bapineuzumab is an anti-amyloid-beta monoclonal antibody, which had shown promise for the treatment of Alzheimer’s Disease. Two double-blind, randomised, placebo-controlled, phase 3 trials have been conducted, involving 2204 patients with mild-to-moderate Alzheimer’s disease. One trial involved 1121 carriers of the apolipoprotein E (APOE) ε4 allele. The other trial involved 1331 non-carriers.
There were some treatment differences in biomarkers for the APOE ε4 carriers. These trials did not, however, find any significant improvement in clinical outcomes.
Salloway, S. Sperling, R. [and] Fox, NC. [et al] (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. New England Journal of Medicine, January 23rd 2014, Vol.370(4), pp.322-33. (Click here to view the PubMed abstract).